Aisling Capital Management LP Takes $2.87 Million Position in Scholar Rock Holding Corporation $SRRK

Aisling Capital Management LP purchased a new position in shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 77,031 shares of the company’s stock, valued at approximately $2,869,000. Scholar Rock comprises 0.6% of Aisling Capital Management LP’s investment portfolio, making the stock its 10th largest holding. Aisling Capital Management LP owned about 0.08% of Scholar Rock as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in SRRK. Norges Bank acquired a new stake in Scholar Rock during the 2nd quarter worth approximately $41,628,000. Balyasny Asset Management L.P. bought a new position in shares of Scholar Rock during the second quarter valued at $33,062,000. Federated Hermes Inc. lifted its holdings in shares of Scholar Rock by 232.1% during the third quarter. Federated Hermes Inc. now owns 800,455 shares of the company’s stock worth $29,809,000 after purchasing an additional 559,455 shares during the period. Bellevue Group AG lifted its holdings in shares of Scholar Rock by 17.6% during the second quarter. Bellevue Group AG now owns 2,947,295 shares of the company’s stock worth $104,393,000 after purchasing an additional 440,405 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in shares of Scholar Rock by 161.0% in the third quarter. JPMorgan Chase & Co. now owns 713,988 shares of the company’s stock worth $26,589,000 after purchasing an additional 440,401 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

Scholar Rock Price Performance

Shares of SRRK opened at $44.31 on Wednesday. The firm has a market cap of $4.52 billion, a PE ratio of -14.07 and a beta of 0.70. Scholar Rock Holding Corporation has a 52-week low of $22.71 and a 52-week high of $49.82. The business’s 50 day moving average price is $45.29 and its two-hundred day moving average price is $39.08. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.30 and a current ratio of 6.30.

Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.86) by $0.10. During the same quarter last year, the company posted ($0.64) EPS. On average, equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current year.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Caryn Parlavecchio sold 9,035 shares of Scholar Rock stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total value of $420,398.55. Following the completion of the sale, the insider directly owned 169,087 shares of the company’s stock, valued at approximately $7,867,618.11. The trade was a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Jing L. Marantz sold 4,157 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $46.53, for a total transaction of $193,425.21. Following the transaction, the insider owned 126,012 shares in the company, valued at $5,863,338.36. This represents a 3.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 344,932 shares of company stock valued at $15,371,225. Company insiders own 13.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on SRRK. Wolfe Research assumed coverage on Scholar Rock in a research report on Tuesday, November 18th. They set an “outperform” rating and a $42.00 target price for the company. Cantor Fitzgerald reiterated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Barclays restated an “overweight” rating and set a $53.00 price objective on shares of Scholar Rock in a research report on Tuesday. UBS Group started coverage on Scholar Rock in a research note on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a report on Thursday, January 22nd. Four research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and an average price target of $52.00.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).